Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its clinical-stage lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.
Metrics to compare | TPST | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipTPSTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.4x | −3.8x | −0.6x | |
PEG Ratio | −0.01 | 0.03 | 0.00 | |
Price/Book | 2.4x | 4.2x | 2.6x | |
Price / LTM Sales | - | 19.1x | 3.2x | |
Upside (Analyst Target) | 188.5% | 88.2% | 41.8% | |
Fair Value Upside | Unlock | −5.9% | 5.1% | Unlock |